Related references
Note: Only part of the references are listed.Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
Sean Khozin et al.
CLINICAL CANCER RESEARCH (2017)
Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions
Paul A. Jackson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping
Michael Juchum et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Determining Cysteines Available for Covalent Inhibition Across the Human Kinome
Zheng Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3
Felix Muth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-(2s,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-y1)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
Atli Thorarensen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site
Marcel Gunther et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes
Qian Zhao et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
Antonio Passaro et al.
PHARMACOLOGICAL RESEARCH (2017)
Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting
Michael Forster et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Structure-guided development of covalent TAK1 inhibitors
Li Tan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Designing Irreversible InhibitorsWorth the Effort?
Concepcion Gonzalez-Bello
CHEMMEDCHEM (2016)
Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase
Francesco Ansideri et al.
ANALYTICAL BIOCHEMISTRY (2016)
Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant
Marcel Guenther et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Targeted Covalent Inhibitors for Drug Design
Thomas A. Baillie
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations
Weiguo Zhang et al.
CANCER RESEARCH (2016)
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma
Daniel W. Bowles et al.
CLINICAL COLORECTAL CANCER (2016)
Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3
Alvin Kung et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)
Proteome-wide covalent ligand discovery in native biological systems
Keriann M. Backus et al.
NATURE (2016)
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia et al.
NATURE (2016)
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Tinghu Zhang et al.
NATURE CHEMICAL BIOLOGY (2016)
Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling
Geoffrey A. Smith et al.
NATURE CHEMICAL BIOLOGY (2016)
I-SPY 2-A Glimpse of the Future of Phase 2 Drug Development?
David Harrington et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
Bin-Chi Liao et al.
JOURNAL OF BIOMEDICAL SCIENCE (2016)
The Intersection of Structural and Chemical Biology - An Essential Synergy
William J. Zuercher et al.
CELL CHEMICAL BIOLOGY (2016)
Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket
Michael Forster et al.
CELL CHEMICAL BIOLOGY (2016)
Development of small molecules targeting the pseudokinase Her3
Sang Min Lim et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Identification and Characterization of an Irreversible Inhibitor of CDK2
Elizabeth Anscombe et al.
CHEMISTRY & BIOLOGY (2015)
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
R. Angelo de Claro et al.
CLINICAL CANCER RESEARCH (2015)
Development of Selective Covalent Janus Kinase 3 Inhibitors
Li Tan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
Prolonged and tunable residence time using reversible covalent kinase inhibitors
J. Michael Bradshaw et al.
NATURE CHEMICAL BIOLOGY (2015)
The ins and outs of selective kinase inhibitor development
Susanne Mueller et al.
NATURE CHEMICAL BIOLOGY (2015)
Ainsliadimer A selectively inhibits IKKα/β by covalently binding a conserved cysteine
Ting Dong et al.
NATURE COMMUNICATIONS (2015)
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
Margit Hagel et al.
CANCER DISCOVERY (2015)
Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
Eric R. Goedken et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Selective Inhibition of Mutant Ras Protein through Covalent Binding
Joachim Rudolph et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Activation of Inflammasomes by Agents Causing Idiosyncratic Skin Reactions: A Possible Biomarker
J. Kyle Weston et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2014)
Design and Synthesis of Tricyclic JAK3 Inhibitors with Picomolar Affinities as Novel Molecular Probes
Matthias Gehringer et al.
CHEMMEDCHEM (2014)
Recently targeted kinases and their inhibitors - the path to clinical trials
Stefan Knapp et al.
CURRENT OPINION IN PHARMACOLOGY (2014)
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
M. Raymond V. Finlay et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Design of Reversible, Cysteine-Targeted Michael Acceptors Guided by Kinetic and Computational Analysis
Shyam Krishnan et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Nicholas Kwiatkowski et al.
NATURE (2014)
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
Apirat Chaikuad et al.
NATURE CHEMICAL BIOLOGY (2014)
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
Bryan R. Lannine et al.
NATURE CHEMICAL BIOLOGY (2014)
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
Li Tan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Recent advances in irreversible kinase inhibitors
Adam M. Gilbert
PHARMACEUTICAL PATENT ANALYST (2014)
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Qingsong Liu et al.
CHEMISTRY & BIOLOGY (2013)
Afatinib: First Global Approval
Rosselle T. Dungo et al.
DRUGS (2013)
The anti-inflammatory compound BAY-11-7082 is a potent inhibitor of protein tyrosine phosphatases
Navasona Krishnan et al.
FEBS JOURNAL (2013)
Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα
Mariana Nacht et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
A Toxicity Risk Index, An Index for Warning Idiosyncratic Drug Toxicity
Miyoshi Morimoto et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors
Rand M. Miller et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Annette O. Walter et al.
CANCER DISCOVERY (2013)
Idiosyncratic Adverse Drug Reactions: Current Concepts
Jack Uetrecht et al.
PHARMACOLOGICAL REVIEWS (2013)
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
Martin Schuler et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species
Vipul Kumar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Discovery of Potent and Selective Covalent Inhibitors of JNK
Tinghu Zhang et al.
CHEMISTRY & BIOLOGY (2012)
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller et al.
LANCET ONCOLOGY (2012)
Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity
Candice E. Paulsen et al.
NATURE CHEMICAL BIOLOGY (2012)
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Iana M. Serafimova et al.
NATURE CHEMICAL BIOLOGY (2012)
Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent Inhibitors
Emeline Leproult et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Irreversible Nek2 Kinase Inhibitors with Cellular Activity
Jeffrey C. Henise et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
The resurgence of covalent drugs
Juswinder Singh et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
In Vivo Efficacy of Natural Product-Inspired Irreversible Kinase Inhibitors
Sofia Barluenga et al.
CHEMBIOCHEM (2010)
A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
Wenjun Zhou et al.
CHEMISTRY & BIOLOGY (2010)
The (un)targeted cancer kinome
Oleg Fedorov et al.
NATURE CHEMICAL BIOLOGY (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Chemical Modification of Proteins at Cysteine: Opportunities in Chemistry and Biology
Justin M. Chalker et al.
CHEMISTRY-AN ASIAN JOURNAL (2009)
A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding
Shintaro Nakayama et al.
DRUG METABOLISM AND DISPOSITION (2009)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Idiosyncratic drug reactions: Past, present, and future
Jack Uetrecht
CHEMICAL RESEARCH IN TOXICOLOGY (2008)
Molecular modeling and crystal structure of ERK2-hypothemycin complexes
Giulio Rastelli et al.
JOURNAL OF STRUCTURAL BIOLOGY (2008)
17-Acetoxyjolkinolide B irreversibly inhibits I kappa B kinase and induces apoptosis of tumor cells
Shou-Sheng Yan et al.
MOLECULAR CANCER THERAPEUTICS (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
Y. Minami et al.
ONCOGENE (2007)
Role of a cysteine residue in the active site of ERK and the MAPKK family
Makoto Ohori et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Polo-like kinases inhibited by Wortmannin - Labeling site and downstream effects
Yongsheng Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Redox regulation of neuronal survival mediated by electrophilic compounds
Takumi Satoh et al.
TRENDS IN NEUROSCIENCES (2007)
Inhibition of NF-κB activation through targeting IκB kinase by celastrol, a quinone methide triterpenoid
Jeong-Hyung Lee et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides
A Schirmer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Structural bioinformatics-based design of selective, irreversible kinase inhibitors
MS Cohen et al.
SCIENCE (2005)
Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity
HR Tsou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
SK Rabindran et al.
CANCER RESEARCH (2004)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Irreversible inhibitors of serine, cysteine, and threonine proteases
JC Powers et al.
CHEMICAL REVIEWS (2002)
Tyrosine kinase inhibitors.: 17.: Irreversible inhibitors of the epidermal growth factor receptor:: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
JB Smaill et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
A Rossi et al.
NATURE (2000)
Share Paper
